English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/169289
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future

AutorValent, Peter; Akin, Cem; Hartmann, Karin; Nilsson, Gunnar; Reiter, Andreas; Hermine, Olivier; Sotlar, Karl; Sperr, Wolfgang R.; Escribano, Luis; George, Tracy I.; Kluin-Nelemans, Hanneke C.; Ustun, Celalettin; Triggiani, Massimo; Brockow, Knut; Gotlib, Jason; Orfao, Alberto ; Schwartz, Lawrence B.; Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten; Kovanen, Petri T.; Galli, Stephen J.; Austen, K. Frank; Arber, Daniel A.; Horny, Hans-Peter; Arock, Michel; Metcalfe, Dean D.
Palabras claveMast cells
Midostaurin
Prognostication
Tryptase
KIT D816V
Mastocytosis
Fecha de publicación2017
EditorAmerican Association for Cancer Research
CitaciónCancer Research 77(6): 1261-1270 (2017)
ResumenMastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced SM.
Versión del editorhttps://doi.org/10.1158/0008-5472.CAN-16-2234
URIhttp://hdl.handle.net/10261/169289
Identificadoresdoi: 10.1158/0008-5472.CAN-16-2234
e-issn: 1538-7445
issn: 0008-5472
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
advanfutur.pdf393,09 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.